Intranasal insulin for treatment of delirium in older hospitalised patients: study protocol for a randomised controlled trial.

ABSTRACT:

Introduction

Delirium is one of the most common conditions diagnosed in hospitalised older people and is associated with numerous adverse outcomes, yet there are no proven pharmacological treatments. Recent research has identified cerebral glucose hypometabolism as a pathophysiological mechanism offering a therapeutic target in delirium. Insulin, delivered via the intranasal route, acts directly on the central nervous system and has been shown to enhance cerebral metabolism and improve cognition in patients with mild cognitive impairment and dementia. This trial will determine whether intranasal insulin can reduce the duration of delirium in older hospitalised patients.

Methods and analysis

This is a prospective randomised, placebo-controlled, double-blind study with 6 month

SUBMITTER: Nitchingham A 

PROVIDER: S-EPMC8527126 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature